Nature Nanotechnology publishes RIVM research on plastics On Thursday 20 January, Nature Nanotechnology published the article Quantitative tracing of uptake and transport of submicrometre plastics in crop plants using lanthanide chelates as a dual-functional tracer.
RIVM study confirms: Tata Steel site is main source of PAHs and metals in the IJmond region A new study conducted by RIVM shows that the PAHs and metals present in the living environment of residents of the IJmond region predominantly originate from the Tata Steel site.
Quality of protective equipment insufficient during COVID-19 crisis The personal protective equipment (PPE) purchased at the national level during the COVID-19 crisis for use in the healthcare sector only partly met the required standards of quality.
200 thousand people tested positive in one week 201,536 positive COVID-19 tests were reported to RIVM last week. That is an increase of 77% compared to the previous week. Such high numbers of reported infections within just one week have never been seen before in the Netherlands.
Omicron causes 35% increase in positive COVID-19 tests, despite lockdown In the past week*, the number of reported positive COVID-19 tests increased by 35% compared to the week before that. The number of people tested by the GGD was about the same.
At least 87% of people over 65 vaccinated at least once: high turnout, few regional differences Four months after the launch of the vaccination campaign, at least 87% of people over 65 in the Netherlands have been vaccinated against COVID-19 at least once.
Quality assessment of SARS-CoV-2 antigen test diagnostics: good performance at public test sites in the Netherlands In their role as WHO reference laboratories, RIVM and Erasmus UMC conducted a study on the quality of SARS-CoV-2 antigen diagnostics in the Netherlands.
Long-term symptoms more common after Lyme disease More than a quarter of people with Lyme disease continue to have long-term symptoms that lead to limitations in daily life even after treatment.
RIVM updates guidelines for AstraZeneca interval As of 21 May, RIVM updated the guidelines for the interval between two doses of the AstraZeneca vaccine. The interval can now be between 6 and 14 weeks.
Social well-being is improving, compliance with coronavirus measures remains important With the recent easing of the coronavirus measures, social contact and well-being are improving again. Compliance with most measures remains stable for now (such as getting tested by the GGD and avoiding crowds) or is decreasing very gradually.